Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Medical Tourism Still Needs A Shot in the Arm

A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.

Tease photo

Epipen Alternative to Bring Good News to Price Sensitive Users

Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.

Tease photo

Life Science Funding Shows Increase in Most Rounds

Financing rounds since 2013 have grown larger in San Diego life sciences. A look at annual median deal size shows an increase, from early-stage seed financing to Series A, C and D rounds. Only Series B rounds have remained flat in recent years.

Tease photo

Neurocrine’s Tourette Syndrome Drug Misses Primary Goal

San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.

Following the Local Biotech VC Funding Trail

The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?

Tease photo

House Bill Would Further Delay Medical Device Tax

Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.

Healthcare District Dumps At-Large Elections

HEALTH: Grossmont Makes Move; Palomar Considers Election Change

Under the threat of a lawsuit from a Malibu attorney, one San Diego hospital district is moving to a new type of election system, while another will consider doing so.

Tease photo

Pfizer Move to Transfer 100 Jobs to San Diego

Pharmaceutical behemoth Pfizer is set to close a South San Francisco site and relocate 100 jobs to its research and development campus in La Jolla.

Tease photo

Report: Human Longevity’s Valuation Falls 80%

Human Longevity Inc.’s latest valuation: $310 million, down more than 80 percent from early 2017, according to the Wall Street Journal.

Oxeia Leading the Pack on Potential Concussion Treatments

Oxeia Leading the Pack on Potential Concussion Treatments

Tease photo

More stories >>